Macrophage-Directed Delivery of Doxorubicin Conjugated to Neoglycoprotein Using Leishmaniasis as the Model Disease

Pijush K. Das, Rupnarayan Sett, Kakali Sarkar

Research output: Contribution to journalArticlepeer-review

Abstract

The antileishmanial potency of doxorubicin conjugated to mannose-human serum albumin (man-HSA) was tested in experimental visceral leishmaniasis. Conjugation of doxorubicin did not decrease the affinity of the neoglycoprotein for the macrophage mannose receptor. Conjugated doxorubicin eliminated intracellular amastigotes of Leishmania donovani in peritoneal macrophages almost 12.5 times more efficiently than did the free drug and greatly reduced and possibly eliminated splenic intracellular parasites in four consecutive dosages at 5 μg/kg/day for 45 days. Free drug at a similar dose had little effect. The leishmanicidal effect of doxorubicin conjugate can be prevented by competitive inhibitors such as man-HSA or mannan and inhibitors of receptor-mediated endocytosis such as colchicine and monensin. These results not only indicate the potential ofdoxorubicin as an effective chemotherapeutic agent for leishmaniasis but also establish the use of mannosylated neoglycoprotein as a drug carrier in the therapy of macrophage- associated diseases.

Original languageEnglish (US)
Pages (from-to)994-999
Number of pages6
JournalJournal of Infectious Diseases
Volume168
Issue number4
DOIs
StatePublished - Oct 1993

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Macrophage-Directed Delivery of Doxorubicin Conjugated to Neoglycoprotein Using Leishmaniasis as the Model Disease'. Together they form a unique fingerprint.

Cite this